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licenses/by/4.0/).Abstract Aim: Chemotherapy results in permanent loss of ovarian function in some premen-
opausal women. Accurate identification in women with hormone-sensitive early breast cancer
(eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess
whether analysis of anti-Mu¨llerian hormone (AMH) using a sensitive automated assay could
identify women who would not regain ovarian function after chemotherapy.
Methods: Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer
Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue)
for ovarian protection were analysed. Women were assessed for premature ovarian insuffi-
ciency (POI: amenorrhoea with elevated follicle-stimulating hormone (FSH)) at 24 months af-
ter diagnosis. The accuracy of AMH for the diagnosis of POI and its prediction from
measurement at the end of chemotherapy was calculated.
Results: AMH below the level of detection showed good diagnostic accuracy for POI at 24
months (n Z 73) with receiver operating characteristic (ROC) area under the curve of 0.86,
sensitivity 1.0 and specificity 0.73 at the assay limit of detection. In women aged >40 at diag-
nosis who did not receive goserelin, AMH measured at end of chemotherapy also gave good
prediction of POI at 24 months (area under the curve (AUC) 0.89 95% CI 0.75e1.0, nZ 32),
with sensitivity 0.91, specificity 0.82, diagnostic odds ratio (DOR) 42.8. FSH gave slightlyfor Reproductive Health, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16
ed.ac.uk (R.A. Anderson).
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R.A. Anderson et al. / European Journal of Cancer 87 (2017) 58e64 59lower AUC, and specificity was low at 0.55. Age but not tamoxifen impacted on AMH levels.
Conclusion: Using this sensitive AMH assay, the finding of an undetectable AMH level in
women aged >40 at the end of chemotherapy for eBC gave a good prediction that ovarian
function would not return. This may allow alterations in post-chemotherapy endocrine man-
agement.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Suppression of ovarian function or blockade of oes-
trogen production or synthesis is a key part of the
treatment of hormone receptor-positive breast cancer
[1]. In premenopausal women suppression of oestrogen
production can be achieved by concurrent administra-
tion of a gonadotrophin-releasing hormone (GnRH)
analogue [2]. The recent trials (Suppression of Ovarian
Function Trial [SOFT] and Tamoxifen and Exemestane
Trial [TEXT]) confirmed the benefit of endocrine ther-
apy to suppress ovarian function in reducing recurrence
rate, although not overall survival [3,4]. However, this
has adverse consequences for patient’s quality of life [5].
Although the loss of growing ovarian follicles during
chemotherapy frequently results in women developing
amenorrhoea [6,7], many subsequently regain ovarian
function and thus, chemotherapy-induced amenorrhoea
does not reliably demonstrate postmenopausal status
[8]. The likelihood of ovarian recovery depends on the
chemotherapeutic regimen, the patient’s age, and pre-
existing ovarian reserve [6,9e13] but there are at pre-
sent no diagnostic tests or predictors of recovery of
sufficient accuracy for clinical use. A more accurate
assessment of ovarian function post chemotherapy
would be valuable and might aid selection of better
endocrine therapy after chemotherapy.
Anti-Mu¨llerian hormone (AMH) is produced by
small growing follicles [14]. Their number indirectly re-
flects the number of remaining primordial follicles, the
true ovarian reserve, necessary for ongoing ovarian
function. Serum AMH falls rapidly during chemo-
therapy [15,16], with variable recovery thereafter
reflecting the degree of ovarian damage and thus post-
treatment ovarian function [9,17e19]. AMH assays have
previously been insufficiently sensitive to be of great
value in diagnosing the menopause, becoming unde-
tectable several years prior to final menses [20], but
recent technological developments have resulted in
markedly improved assay sensitivity [21]. Using one
such highly sensitive assay, we have shown that women
who were premenopausal at breast cancer diagnosis but
who subsequently develop amenorrhoea and undetect-
able AMH following chemotherapy are very likely to
remain amenorrhoeic [22]. We report an analysis of
serum AMH in relation to post-chemotherapy ovarianfunction in women treated for breast cancer as part of
the OPTION trial, to assess the diagnostic accuracy of
AMH for POI following recovery from chemotherapy,
and the potential for early post-chemotherapy AMH
levels to predict that recovery.
2. Methods
OPTION was a Randomised Controlled Trial (RCT) of
the effect of goserelin administration during chemo-
therapy to reduce ovarian toxicity [23], Trial registration:
EudraCT 2004-000133-11. In brief, the study population
consisted of premenopausal women with histologically
confirmed breast cancer who were to receive adjuvant or
neo-adjuvant chemotherapy. Patients were randomised
to receive goserelin 3.6 mg monthly from shortly before
chemotherapy until the end of chemotherapy; regimens
included 6e8 cycles of cyclophosphamide and/or
anthracycline-containing regimens with or without a
taxane. The primary outcome was the prevalence of
amenorrhoea at 12e24months after diagnosis, supported
by hormone measurements to allow the diagnosis of
premature ovarian insufficiency (POI), defined as ame-
norrhoea plus follicle-stimulating hormone (FSH) con-
centration >25 IU/l, with patients divided in two age
cohorts, 40 versus >40 years at diagnosis. All patients
gave informed consent, and the study received Ethical
Committee approval.
Hormone analyses were available on a subset of
women, with samples for this analysis taken pre-treat-
ment, at the end of chemotherapy, and 12 and 24 months
after diagnosis. FSH, oestradiol (E2) and AMH were
measured in serum using the Roche Elecsys system. The
AMH assay has a limit of detection of 0.07 pmol/l
(0.010 ng/ml), the oestradiol assay (Oestradiol III) has a
limit of detection of 18.4 pmol/l and limit of quantifica-
tion of 61.3 pmol/l.
Hormone data were not normally distributed and are
presented as median 95% confidence intervals. Statis-
tical analysis to assess hormone concentration changes
from the end of chemotherapy was by Kruskale-Wallis
- test with Dunn’s multiple comparison tests, with
further analysis by menstrual function/POI, and age
(40 versus >40 years at diagnosis). Analysis of diag-
nostic value was performed by generating ROC curves,
and calculation of sensitivity, specificity and likelihood
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limit of detection) and 25 IU/l for FSH [24]. Cut-off
values for AMH and FSH in analysis of pre-
chemotherapy samples were derived from the combi-
nation of sensitivity and specificity giving the highest
LR. Positive and negative predictive values (PPV and
NPV), and diagnostic odd ratio (DOR) were also
calculated. Data from all available patients were used
for the diagnostic analysis in relation to whether or not
women had POI (amenorrhoea between 12 and 24
months after diagnosis, with FSH>25 IU/l). The pre-
dictive analysis of hormonal data at end of chemo-
therapy versus later amenorrhoea/POI was confined to
the control group who did not receive goserelin, to avoid
any impact of goserelin on AMH and FSH levels [15].
Prediction of later POI by pre-treatment hormone con-
centrations was performed using data from all women as
those time points were distant from goserelin adminis-
tration. Baseline characteristics of women included in
this analysis are given in Table 1.
3. Results
Serum concentrations of E2, FSH and AMH during the
course of the study are shown in Fig. 1. Compared with
women with ovarian function at 24 months, E2 con-
centrations at the end of treatment were lower in women
with subsequent POI (pZ 0.0003) and continued to fall
(p Z 0.009 at 24 months versus end of treatment), with
no changes beyond the end of treatment in women who
did not develop POI. FSH was significantly higher at the
end of treatment in women with POI (p Z 0.001) and
did not change thereafter, whereas there was a small fall
after treatment completion in women without POI
(p Z 0.03). Women who developed POI had lower pre-
treatment AMH concentrations (pZ 0.0002) than those
who did not. AMH concentrations were markedly
reduced at the end of treatment in all women compared
to pre-treatment, and lower in women who subsequently
had POI than those who did not (p < 0.0001). From the
end of treatment, AMH concentrations showed a small
increase in women without POI at 12 months
(p Z 0.006) with no further rise at 24 months, and
women with POI had lower AMH concentrations at 24
months than those who did not (p < 0.0001).Table 1
Baseline characteristics of women in these analyses.
All women Controls only
n 101 68
Age (years) 39.5  0.5 39.5  0.6
Proportion of controls 52% 100
Baseline FSH (IU/l) 8.1  0.7 9.0  0.9
Baseline AMH (pmol/l) 9.6  1.2 8.2  1.5
All data are mean  sem. Data for the Control group are those women
not treated with GnRHa who were included in the analysis of end of
treatment AMH and FSH versus POI.Younger women (40 years) showed a significant in-
crease in AMH (p < 0.0001) and fall in FSH (pZ 0.004)
from the end of chemotherapy, whereas women aged over
40 years showed no significant post-treatment changes in
these hormones (Fig. 2). AMH was detectable at the end
of chemotherapy in 35%of women aged over 40, versus in
84% in women aged 40 (p Z 0.0002). There were no
changes in E2 in either age group although it tended to be
higher and more variable in the younger group. Tamox-
ifen was taken by 38% of women, equally distributed by
POI (p Z 0.6). AMH concentrations at both 12 and 24
months were unaffected by tamoxifen administration (at
24 months: 2.5  0.9 with tamoxifen versus
2.1  0.7 pmol/l) and the distinction by POI was un-
changed (with tamoxifen: AMH in POI 0.07 0.0 versus
not POI 3.5  1.2 pmol/l; p < 0.001).
The diagnostic accuracy of AMH and FSH for POI
was assessed by ROC curve. There were no differences
by goserelin treatment in women who were or were not
amenorrhoeic at 12e24 months or who had POI at that
time, thus for those analyses data from all women were
used. For classification by amenorrhoea only, using
hormone concentrations at 24 months, the ROC for
AMH had an AUC of 0.84, sensitivity 86%, specificity
78%, LR 4.0 (Fig. 3A and table). Similarly, the ROC for
FSH at 25 U/l had an AUC of 0.82, sensitivity 76%,
specificity 71%, LR 2.1 (Fig. 3A). PPV, NPV and DOR
calculations also showed a small advantage of AMH
over FSH (Table 1).
ROC analysis for diagnosis of POI (Fig. 3B and
Table 1) gave an AUC of 0.86 for AMH, sensitivity
100%, specificity 73%, and LR 3.7. For FSH, the AUC
was 0.85 sensitivity 100%, specificity 66%, LR 3.0, again
indicating the value of AMH for the diagnosis of POI,
despite FSH>25 IU/l being one of the diagnostic criteria
and hence sensitivity and NPV being 100%.
Data from the control group only were analysed to
assess the value of AMH and FSH measured at the end
of chemotherapy for prediction of POI at 24 months
(Fig. 4A and table). The AUC for the AMH ROC was
0.84, sensitivity 78% specificity 82%, LR 4.4 and for
FSH, the AUC was 0.72, sensitivity 91%, specificity
47%, LR 1.6. PPV and NPV analysis (table) also showed
similar results, with a higher PPV for AMH despite the
lower sensitivity, reflecting the poor specificity of FSH in
this predictive analysis.
The importance of age in the recovery of ovarian
function following chemotherapy was confirmed in this
analysis (Fig. 2) with only two of 52 women aged 40
on whom AMH data were available developing POI. A
ROC curve for the potential value of AMH measure-
ment at the end of chemotherapy for prediction of POI
was therefore calculated for women aged over
40 years at diagnosis in the control group, thus also
avoiding any potential effect of goserelin (Fig. 4B and
Table 2). The AUC for AMH was 0.89, sensitivity 91%,
specificity 82% with LR 5.0, compared to AUC of 0.77,
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Fig. 1. Serum oestradiol (A), FSH (B) and AMH (C) at pre-treatment baseline, end of treatment (EOT) and at 12 and 24 months after
diagnosis, by POI at 24 months. Data from all women from the OPTION trial. Red, women without POI; blue: women with POI
(amenorrhoea plus FSH >25IL/L at 24 months). N Z 96 and 28 respectively; median 95% confidence intervals.
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Fig. 3. ROC curve analysis of AMH (red) and FSH (blue) at 24 months for (A) analysis of amenorrhoea versus ongoing menses (nZ 22
and 51 respectively); (B) for diagnosis of POI versus not POI (n Z 14 and 59 respectively). Data from all women in OPTION included.
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PPV for AMH was 0.90, versus 0.81 for FSH. There
were no E2 levels above 100 pmol/l at either later time
point in women with undetectable AMH at end of
treatment (Fig. 4C).
The predictive value of pre-treatment hormone con-
centrations was also assessed, categorising women as
POI or not, using data from all women (nZ 101; Table
2). For AMH the AUC was 0.77, with peak LR 9.3 at
AMH of <7.3 pmol/l, sensitivity 95%, specificity 49%,
PPV 0.30 and NPV 0.98. For FSH, the AUC was 0.72,
with peak LR 7.7 at FSH >4.3 IU/l, at which concen-
tration sensitivity was 89% and specificity 43%, PPV
0.27, NPV 0.95.4. Discussion
These data indicate that measurement of AMH following
chemotherapy for breast cancer using the improved
sensitivity of the Roche Diagnostics automated Elecsys
assay is an accurate diagnostic test of menopausal status
after recovery from treatment, and that analysis at the end
of chemotherapy may predict POI. For the predictive
analysis, ROC curve analysis gave an AUC of 0.89,
likelihood ratio of 5.0 and DOR of 42.8: values for
AUC > 0.9, LR > 7 and DOR > 20 are regarded as
indicating high accuracy [25] supporting the potential
value of this biomarker. Analysis of AMH as a diagnostic
test for POI at 24 months after diagnosis indicated
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Fig. 4. ROC curve analysis of (A) AMH (red) and FSH (blue) at end of treatment for prediction of POI versus not POI at 24 months
(nZ 23 and 45 respectively) for all women in the OPTION control group. (B) AMH (red) and FSH (blue) serum concentrations at end of
treatment for prediction of POI versus not POI at 24 months for women aged >40 years in the control group in OPTION (nZ 21 and 11
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analysis in women treated for breast cancer when AMH
was measured using a less sensitive assay [26].
The menstrual and endocrine changes of the meno-
pausal transition have been documented in detail in
normal women, but that classification specifically ex-
cludes women treated with chemotherapy [27]. The
choice of endocrine agent after chemotherapy depends
on menopausal status. Prediction of POI is well estab-
lished to be dependent on age [6,7,13] but the value of
biochemical markers has been unclear [28]. Thus, in a
recent analysis, women showing ovarian recovery did
not show differential FSH concentrations [29]. We have
previously suggested that high-sensitivity AMH assays
may be of value in this situation [22]. Here we have
performed a more detailed analysis using a larger inde-
pendent cohort of women, and assessed the value of
post-chemotherapy AMH as a predictor of later POI.
Despite including a threshold level of FSH in the clas-
sification of POI, AMH performed better than FSH.
Analysis of AMH and FSH as diagnostic tests for
amenorrhoea versus menses at 24 months showed that
an undetectable AMH level gave high sensitivity and
specificity with ROC values for AUC, with sensitivity
and specificity all better than for FSH. Classification ofwomen as having POI or not also showed high diag-
nostic accuracy with AMH (sensitivity 100%; specificity
73%), thus AMH was undetectable using this highly
sensitive assay in all women with POI at 24 months.
Tamoxifen did not affect AMH concentrations, as pre-
viously reported [30,31].
The potential value of AMH at the end of chemo-
therapy in identifying POI was examined. AMH levels
were very low in all women following chemotherapy, but
were markedly higher in women who did not subse-
quently have POI at 24 months compared to those who
did, highlighting the value of using this assay with
improved sensitivity. Thereafter a small increase in
AMH was seen in those women who were later classified
as not having POI, whereas there was no recovery in
those who with POI. This shows the value of AMH in
identifying even very low levels of ovarian follicular
activity in this context.
Because of the impact of goserelin treatment on
hormone concentrations at the end of chemotherapy,
further analyses of the predictive value of AMH and
FSH were performed using data only from the control
group, and from women aged over 40 as the initial
analysis confirmed the importance of age as a predictor
of recovery [7,10,13]. AMH also showed significant
Table 2
Analysis of accuracy of AMH and FSH for diagnosis (at 24 months)
and prediction (from end of chemotherapy [EOT] and pre-treatment
versus POI at 24 months) of amenorrhoea and POI at 24 months.
Analysis ROC AUC
(95% CI)
Sensitivity Specificity LR PPV NPV DOR
Diagnosis by amenorrhoea at 24 months (n [ 73)
AMH 0.84
(0.75e0.93)
0.86 0.78 4.0 0.63 0.93 23.0
FSH 0.81
(0.72e0.91)
0.86 0.71 2.9 0.56 0.92 15.2
Diagnosis by POI at 24 months (n Z 73)
AMH 0.86
(0.78e0.95)
1.0 0.73 3.7 0.47 1.0 n/a
FSH 0.85
(0.77e0.94)
1.0 0.66 3.0 0.41 1.0 n/a
Prediction of POI from EOT (all control group, n Z 68)
AMH 0.84
(0.73e0.94)
0.78 0.82 4.4 0.69 0.83 10.9
FSH 0.72
(0.60e0.84)
0.91 0.47 1.6 0.48 0.86 5.5
Prediction of POI from EOT (age > 40 control group only n Z 32)
AMH 0.89
(0.75e1.0)
0.91 0.82 5.0 0.90 0.82 42.8
FSH 0.77
(0.57e0.97)
1.0 0.55 2.2 0.81 1.0 n/a
Prediction of POI by pre-treatment hormones (n Z 101)
AMH 0.77
(0.65e0.88)
0.95 0.49 9.3 0.30 0.98 17.1
FSH 0.72
(0.60e0.84)
0.89 0.43 7.7 0.27 0.95 6.5
For analysis of amenorrhoea and diagnosis of POI at 24 months, all
women from OPTION are included where data are available. For
prediction of POI, only women in the control group were included. For
all ROC analysis, AUC p < 0.0001 except for prediction of POI from
hormones at end of treatment in >40 age group: pZ 0.0003 for AMH
and p Z 0.01 for FSH, and for pre-treatment prediction of POI,
p Z 0.0003 for AMH, p Z 0.028 for FSH.
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with FSH showing lower diagnostic accuracy. The
higher specificity for AMH demonstrates its ability to
reflect very low levels of ovarian activity when FSH is in
the menopausal range, activity that will then increase in
many women after chemotherapy. AMH may also be
only transiently detectable at the end of chemotherapy
in some women, indicating menopausal onset after
ageing-related loss of a very small amount of residual
activity present at the end of chemotherapy.
A small proportion of women, even those in their late
40s at diagnosis, can show late recovery of ovarian
function [32]. In this analysis, POI at 24 months was
used, thus few women would be likely to have ame-
norrhoea/POI at that time and still show later recovery
of ovarian function, but any such women would reduce
the diagnostic accuracies reported here. A further limi-
tation of this study is the need to include only the con-
trol group (i.e. not treated with goserelin) in the
predictive analysis, thus reducing the number of women
evaluable.
Pre-treatment AMH was confirmed to be predictive
of POI following chemotherapy [9,10,33]. An optimalcut-point of 7.3 pmol/l pre-treatment was identified,
which showed good sensitivity but poor specificity.
While age is also an important predictor [6,10], this in-
formation may be of value in identifying women at
particular risk of loss of fertility following chemo-
therapy, although fertility can be retained in women
with even very low AMH levels [34]. Conversely, AMH
above that threshold showed very good prediction of
not having POI at 24 months.
In conclusion, these data show that using a highly
sensitive assay, measurement of AMH at the end of
chemotherapy can identify women who will show
ovarian recovery with good precision. Conversely, un-
detectable AMH at end of chemotherapy may be useful
in identifying women who will not show ovarian re-
covery, which could influence choice of endocrine ther-
apy by avoiding the need for ovarian suppression.
Larger prospective trials are needed to validate the role
of AMH in oncology clinical practice.
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